The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO GI 2026 | EMERALD-3 & EMERALD-1 reshape TACE strategies in HCC at ESMO GI 2026
Silvio Ken Garattini, MD, Azienda Sanitaria Universitaria Friuli Centrale, Udine, Italy, discusses the results of the EMERALD-3 (NCT05301842) and EMERALD-1 (NCT03778957) clinical trials for the treatment of hepatocellular carcinoma (HCC), highlighting the progression-free survival benefits of sorafenib plus lenvatinib and transarterial chemoembolisation (TACE), as well as the combination of durvalumab, bevacizumab, and TACE. While overall survival data are still pending for the EMERALD-3 trial, the results suggest that sorafenib plus lenvatinib could be a viable option to add to TACE, particularly for patients with intermediate-risk HCC. This interview took place at the European Society for Medical Oncology (ESMO) Gastrointestinal Cancer 2026 Congress in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
